Gilead Sciences
GILD
1,682 hedge funds and large institutions have $78.1B invested in Gilead Sciences in 2023 Q3 according to their latest regulatory filings, with 130 funds opening new positions, 684 increasing their positions, 632 reducing their positions, and 127 closing their positions.
13% more call options, than puts
Call options by funds: $919M | Put options by funds: $816M
7% more funds holding in top 10
Funds holding in top 10: 29 → 31 (+2)
8% more repeat investments, than reductions
Existing positions increased: 684 | Existing positions reduced: 632
2% more first-time investments, than exits
New positions opened: 130 | Existing positions closed: 127
0.29% less ownership
Funds ownership: 83.76% → 83.47% (-0.29%)
3% less capital invested
Capital invested by funds: $80.6B → $78.1B (-$2.48B)
1% less funds holding
Funds holding: 1,702 → 1,682 (-20)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
+$224M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$124M |
| 3 |
Two Sigma Investments
New York
|
+$123M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$102M |
| 5 |
JP Morgan Chase
New York
|
+$70.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$217M |
| 2 |
Bank of New York Mellon
New York
|
-$159M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$130M |
| 4 |
Renaissance Technologies
New York
|
-$103M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$96.1M |
GILD Hedge Fund Activity: Q3 2023 in Review
1,682 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2023, worth a combined $78.1B — down 3.1% from $80.6B a quarter earlier.
Buyers outnumbered sellers: 130 funds opened new GILD positions and 127 closed out — a net gain of 3 holders — while 684 added to existing stakes and 632 trimmed.
The largest buyer was ClearBridge Investments, adding an estimated $224M. The largest seller was Barclays, cutting an estimated $217M.
- 1,682 institutional investors held Gilead Sciences (GILD) as of Q3 2023, down from 1,702 in Q2 2023.
- Funds reported $78.1B of Gilead Sciences stock for Q3 2023, down 3.1% quarter-over-quarter.
- 130 funds opened new Gilead Sciences positions in Q3 2023 and 127 closed out, a net change of +3 holders.
- The largest Gilead Sciences buyer in Q3 2023 was ClearBridge Investments, an estimated $224M added.
- The largest Gilead Sciences seller in Q3 2023 was Barclays, an estimated $217M sold.
Based on aggregated 13F filings for Q3 2023.